These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27522919)

  • 1. Accelerating Vaccine Formulation Development Using Design of Experiment Stability Studies.
    Ahl PL; Mensch C; Hu B; Pixley H; Zhang L; Dieter L; Russell R; Smith WJ; Przysiecki C; Kosinski M; Blue JT
    J Pharm Sci; 2016 Oct; 105(10):3046-3056. PubMed ID: 27522919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Propylene Glycol-Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging.
    Mensch CD; Davis HB; Blue JT
    PDA J Pharm Sci Technol; 2015; 69(4):477-98. PubMed ID: 26242785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.
    Kumru OS; Joshi SB; Smith DE; Middaugh CR; Prusik T; Volkin DB
    Biologicals; 2014 Sep; 42(5):237-59. PubMed ID: 24996452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A heat-stable hepatitis B vaccine formulation.
    Jezek J; Chen D; Watson L; Crawford J; Perkins S; Tyagi A; Jones-Braun L
    Hum Vaccin; 2009 Aug; 5(8):529-35. PubMed ID: 19556877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modern Vaccines/Adjuvants Formulation Session 6: Vaccine &Adjuvant Formulation & Production 15-17 May 2013, Lausanne, Switzerland.
    Fox CB
    Hum Vaccin Immunother; 2013 Sep; 9(9):2007-8. PubMed ID: 23787558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations.
    Vecchi S; Bufali S; Skibinski DA; O'Hagan DT; Singh M
    J Pharm Sci; 2012 Jan; 101(1):17-20. PubMed ID: 21918987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants.
    Peek LJ; Martin TT; Elk Nation C; Pegram SA; Middaugh CR
    J Pharm Sci; 2007 Mar; 96(3):547-57. PubMed ID: 17080408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rational, systematic approach for the development of vaccine formulations.
    Morefield GL
    AAPS J; 2011 Jun; 13(2):191-200. PubMed ID: 21347616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
    Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
    Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal adjuvants: preparation and formulation with antigens.
    Haensler J
    Methods Mol Biol; 2010; 626():73-90. PubMed ID: 20099122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of protein stability in rod-insert vaginal rings.
    Pattani A; Lowry D; Curran RM; McGrath S; Kett VL; Andrews GP; Malcolm RK
    Int J Pharm; 2012 Jul; 430(1-2):89-97. PubMed ID: 22486955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Vaccine Formulation Laboratory: a platform for access to adjuvants.
    Collin N; Dubois PM
    Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serogroup B meningococcal vaccines.
    Zimmer SM; Stephens DS
    Curr Opin Investig Drugs; 2006 Aug; 7(8):733-9. PubMed ID: 16955685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-meningococcal vaccines].
    Taha MK; Alonso JM
    Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.
    Clapp T; Siebert P; Chen D; Jones Braun L
    J Pharm Sci; 2011 Feb; 100(2):388-401. PubMed ID: 20740674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preformulation Characterization, Stabilization, and Formulation Design for the Acrylodan-Labeled Glucose-Binding Protein SM4-AC.
    Sahni N; Chaudhuri R; Hickey JM; Manikwar P; D'Souza A; Metters A; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2017 May; 106(5):1197-1210. PubMed ID: 28088457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New vaccines require potent adjuvants like AFPL1 and AFCo1.
    Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
    Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method.
    Chen D; Kapre S; Goel A; Suresh K; Beri S; Hickling J; Jensen J; Lal M; Preaud JM; Laforce M; Kristensen D
    Vaccine; 2010 Jul; 28(31):5093-9. PubMed ID: 20478345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.